Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 15;8:1773. doi: 10.3389/fimmu.2017.01773

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Shaim, Estrov, Harris, Hernandez Sanabria, Liu, Ruvolo, Thompson, Ferrajoli, Daher, Burger, Muftuoglu, Imahashi, Li, Liu, Alsuliman, Basar, Nassif Kerbauy, Sobieski, Gokdemir, Kondo, Wierda, Keating, Shpall and Rezvani.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Lenalidomide reverses chronic lymphocytic leukemia (CLL)-induced T-cell dysfunction in vivo. Peripheral blood mononuclear cells (PBMCs) were collected from five patients treated with lenalidomide monotherapy (clinical trial 2006-0715, NCT00535873) before and after 3 months of treatment. T-cell function improved after lenalidomide monotherapy. T cells were stimulated with anti-CD3/CD28 beads for 6 h and stained for IFN-γ, TNF-α, IL-2, and CD107a. FACS plots are gated on live CD3+ cells.